ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat

Products from BPS Bioscience require a minimum order value above 400€

Applications: Characterize the Fc effector function of antibodies.

Background: Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages.

Description: Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant.

Format: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO

Host Cell Line: Jurkat

Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, cat. #MP0025) to confirm the absence of Mycoplasma species.

Storage Stability: Immediately upon receipt, store in liquid nitrogen.

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-1

• Artikelnummer: BPS71273
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 71273
• Verpackungseinheit: 2 vials
• Mengeneinheit: PAK
• Wirt: Human